TY - BOOK PY - 2017 DA - 2017// TI - IDF diabetes atlas ID - ref1 ER - TY - JOUR PY - 2016 DA - 2016// TI - Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31678-6 DO - 10.1016/S0140-6736(16)31678-6 ID - ref2 ER - TY - JOUR PY - 1998 DA - 1998// TI - United Kingdom prospective diabetes study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy JO - Ann Intern Med VL - 128 UR - https://doi.org/10.7326/0003-4819-128-3-199802010-00001 DO - 10.7326/0003-4819-128-3-199802010-00001 ID - ref3 ER - TY - JOUR AU - Stark Casagrande, S. AU - Fradkin, J. E. AU - Saydah, S. H. AU - Rust, K. F. AU - Cowie, C. C. PY - 2013 DA - 2013// TI - The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010 JO - Diabetes Care VL - 36 UR - https://doi.org/10.2337/dc12-2258 DO - 10.2337/dc12-2258 ID - Stark Casagrande2013 ER - TY - JOUR AU - Fonseca, V. AU - Gill, J. AU - Zhou, R. AU - Leahy, J. PY - 2011 DA - 2011// TI - An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia JO - Diabetes Obes Metab VL - 13 UR - https://doi.org/10.1111/j.1463-1326.2011.01412.x DO - 10.1111/j.1463-1326.2011.01412.x ID - Fonseca2011 ER - TY - JOUR AU - Daniel, J. D. PY - 2003 DA - 2003// TI - Enhancing incretin action for the treatment of type 2 diabetes JO - Diabetes Care VL - 26 UR - https://doi.org/10.2337/diacare.26.10.2929 DO - 10.2337/diacare.26.10.2929 ID - Daniel2003 ER - TY - JOUR AU - Fonseca, V. AU - Schweizer, A. AU - Albrecht, D. AU - Baron, M. A. AU - Chang, I. AU - Dejager, S. PY - 2007 DA - 2007// TI - Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes JO - Diabetologia VL - 50 UR - https://doi.org/10.1007/s00125-007-0633-0 DO - 10.1007/s00125-007-0633-0 ID - Fonseca2007 ER - TY - JOUR AU - Cheng, T. M. PY - 2003 DA - 2003// TI - Taiwan’s new national health insurance program: genesis and experience so far JO - Health Aff (Millwood) VL - 22 UR - https://doi.org/10.1377/hlthaff.22.3.61 DO - 10.1377/hlthaff.22.3.61 ID - Cheng2003 ER - TY - JOUR AU - Wu, C. Y. AU - Chen, Y. J. AU - Ho, H. J. AU - Hsu, Y. C. AU - Kuo, K. N. AU - Wu, M. S. PY - 2012 DA - 2012// TI - Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection JO - JAMA VL - 308 UR - https://doi.org/10.1001/2012.jama.11975 DO - 10.1001/2012.jama.11975 ID - Wu2012 ER - TY - STD TI - Hicks KA, James Hung HM, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, et al. Standardized definitions for cardiovascular and stroke end point events in Clinical Trials. Draft Definitions CDISC. 2014. https://mdepinet.org/wp-content/uploads/S_1_6_Hicks.pdf. Accessed 31 May 2018. UR - https://mdepinet.org/wp-content/uploads/S_1_6_Hicks.pdf ID - ref10 ER - TY - JOUR AU - D’Agostino, R. B. PY - 1998 DA - 1998// TI - Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group JO - Stat Med VL - 17 UR - https://doi.org/3.0.CO;2-B DO - 3.0.CO;2-B ID - D’Agostino1998 ER - TY - BOOK AU - Iezzoni, L. I. PY - 1997 DA - 1997// TI - Risk adjustment for measuring healthcare outcomes PB - Health Administration Press CY - Chicago, IL ID - Iezzoni1997 ER - TY - JOUR AU - Hong, E. S. AU - Khang, A. R. AU - Yoon, J. W. AU - Kang, S. M. AU - Choi, S. H. AU - Park, K. S. PY - 2012 DA - 2012// TI - Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study JO - Diabetes ObesMetab. VL - 14 ID - Hong2012 ER - TY - JOUR AU - Lukashevich, V. AU - Schweizer, A. AU - Foley, J. E. AU - Dickinson, S. AU - Groop, P. H. AU - Kothny, W. PY - 2013 DA - 2013// TI - Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment JO - Vasc Health Risk Manag VL - 9 UR - https://doi.org/10.2147/VHRM.S39300 DO - 10.2147/VHRM.S39300 ID - Lukashevich2013 ER - TY - JOUR AU - Kothny, W. AU - Foley, J. AU - Kozlovski, P. AU - Shao, Q. AU - Gallwitz, B. AU - Lukashevich, V. PY - 2013 DA - 2013// TI - Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus JO - Diabetes ObesMetab. VL - 15 ID - Kothny2013 ER - TY - JOUR AU - Kozlovski, P. AU - Foley, J. AU - Shao, Q. AU - Lukashevich, V. AU - Kothny, W. PY - 2013 DA - 2013// TI - Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes JO - World J Diabetes VL - 4 UR - https://doi.org/10.4239/wjd.v4.i4.151 DO - 10.4239/wjd.v4.i4.151 ID - Kozlovski2013 ER - TY - JOUR AU - Barnett, A. H. AU - Charbonnel, B. AU - Donovan, M. AU - Fleming, D. AU - Chen, R. PY - 2012 DA - 2012// TI - Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin JO - Curr Med Res Opin VL - 28 UR - https://doi.org/10.1185/03007995.2012.665046 DO - 10.1185/03007995.2012.665046 ID - Barnett2012 ER - TY - JOUR AU - Arnolds, S. AU - Dellweg, S. AU - Clair, J. AU - Dain, M. P. AU - Nauck, M. A. AU - Rave, K. PY - 2010 DA - 2010// TI - Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof of concept study JO - Diabetes Care VL - 33 UR - https://doi.org/10.2337/dc09-2191 DO - 10.2337/dc09-2191 ID - Arnolds2010 ER - TY - JOUR AU - Yki-Jarvinen, H. AU - Rosenstock, J. AU - Duran-Garcia, S. AU - Pinnetti, S. AU - Bhattacharya, S. AU - Thiemann, S. PY - 2013 DA - 2013// TI - Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study JO - Diabetes Care VL - 36 UR - https://doi.org/10.2337/dc12-2718 DO - 10.2337/dc12-2718 ID - Yki-Jarvinen2013 ER - TY - JOUR AU - Vilsbøll, T. AU - Rosenstock, J. AU - Yki-Jarvinen, H. AU - Cefalu, W. T. AU - Chen, Y. AU - Luo, E. PY - 2010 DA - 2010// TI - Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes JO - Diabetes ObesMetab. VL - 12 ID - Vilsbøll2010 ER - TY - JOUR AU - Scirica, B. M. AU - Bhatt, D. L. AU - Braunwald, E. AU - Steg, P. G. AU - Davidson, J. AU - Hirshberg, B. PY - 2013 DA - 2013// TI - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1307684 DO - 10.1056/NEJMoa1307684 ID - Scirica2013 ER - TY - JOUR AU - White, W. B. AU - Cannon, C. P. AU - Heller, S. R. AU - Nissen, S. E. AU - Bergenstal, R. M. AU - Bakris, G. L. PY - 2013 DA - 2013// TI - Alogliptin after acute coronary syndrome in patients with type 2 diabetes JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305889 DO - 10.1056/NEJMoa1305889 ID - White2013 ER - TY - JOUR AU - Green, J. B. AU - Bethel, M. A. AU - Armstrong, P. W. AU - BuseJ, B. AU - Engel, S. S. AU - Garg, J. PY - 2015 DA - 2015// TI - Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1501352 DO - 10.1056/NEJMoa1501352 ID - Green2015 ER - TY - JOUR AU - Pasquel, F. J. AU - Gianchandani, R. AU - Rubin, D. J. AU - Dungan, K. M. AU - Anzola, I. AU - Gomez, P. C. PY - 2017 DA - 2017// TI - Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial JO - Lancet Diabetes Endocrinol VL - 5 UR - https://doi.org/10.1016/S2213-8587(16)30402-8 DO - 10.1016/S2213-8587(16)30402-8 ID - Pasquel2017 ER - TY - JOUR AU - Zinman, B. AU - Ahrén, B. AU - Neubacher, D. AU - Patel, S. AU - Woerle, H. J. AU - Johansen, O. E. PY - 2016 DA - 2016// TI - Efficacy and cardiovascular safety of linagliptin as an add-on to insulin in type 2 diabetes: a pooled comprehensive post hoc analysis JO - Can J Diabetes VL - 40 UR - https://doi.org/10.1016/j.jcjd.2015.06.010 DO - 10.1016/j.jcjd.2015.06.010 ID - Zinman2016 ER - TY - JOUR AU - Barbieri, M. AU - Rizzo, M. R. AU - Marfella, R. AU - Boccardi, V. AU - Esposito, A. AU - Pansini, A. PY - 2013 DA - 2013// TI - Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors JO - Atherosclerosis VL - 227 UR - https://doi.org/10.1016/j.atherosclerosis.2012.12.018 DO - 10.1016/j.atherosclerosis.2012.12.018 ID - Barbieri2013 ER - TY - JOUR AU - Ussher, J. R. AU - Drucker, D. J. PY - 2012 DA - 2012// TI - Cardiovascular biology of the incretin system JO - Endocr Rev VL - 33 UR - https://doi.org/10.1210/er.2011-1052 DO - 10.1210/er.2011-1052 ID - Ussher2012 ER - TY - JOUR AU - Hibuse, T. AU - Maeda, N. AU - Kishida, K. AU - Kimura, T. AU - Minami, T. AU - Takeshita, E. AU - Hirata, A. AU - Nakagawa, Y. AU - Kashine, S. AU - Oka, A. AU - Hayashi, M. AU - Nishizawa, H. AU - Funahashi, T. AU - Shimomura, I. PY - 2014 DA - 2014// TI - A pilot 3-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus— a randomized controlled trial START-J study JO - Cardiovas Diabetol VL - 13 UR - https://doi.org/10.1186/1475-2840-13-96 DO - 10.1186/1475-2840-13-96 ID - Hibuse2014 ER - TY - JOUR AU - Li, H. Y. AU - Jiang, Y. D. AU - Chang, C. H. AU - Chung, C. H. AU - LinB, J. AU - Chuang, L. M. PY - 2012 DA - 2012// TI - Mortality trends in patients with diabetes in Taiwan: a nationwide survey in 2000-2009 JO - J Formos Med Assoc VL - 111 UR - https://doi.org/10.1016/j.jfma.2012.09.013 DO - 10.1016/j.jfma.2012.09.013 ID - Li2012 ER - TY - JOUR AU - Charbonnel, B. AU - DeFronzo, R. AU - Davidson, J. AU - Schmitz, O. AU - Birkeland, K. AU - Pirags, V. PY - 2010 DA - 2010// TI - Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19) JO - J ClinEndocrinolMetab VL - 95 UR - https://doi.org/10.1210/jc.2009-1974 DO - 10.1210/jc.2009-1974 ID - Charbonnel2010 ER -